Pediatric Radiology

, Volume 43, Issue 9, pp 1159–1165 | Cite as

Deferoxamine-induced dysplasia-like skeletal abnormalities at radiography and MRI

  • Hadeel M. Seif El Dien
  • Reem I. Esmail
  • Rania E. Magdy
  • Hala M. LotfyEmail author
Original Article



Current thalassemia major treatment includes blood transfusion and iron chelation, which is associated with growth disturbances and radiographic changes in the long bone metaphyses.


To explore and discuss the spectrum of deferoxamine-induced bone-dysplasia-like changes in children with thalassemia major in Egypt.

Materials and methods

We studied 59 Egyptian children with thalassemia major and generalized arthralgia. All started deferoxamine treatment at 3 years of age. We conducted skeletal survey and MRI of both knees in radiographically positive children. Each child’s age, serum ferritin, age of onset and duration of therapy were compared with the radiologic findings.


Twenty-two (37.3%) children had variable degrees of skeletal dysplasia-like changes similar to those described with deferoxamine intake, mostly around the knees. Mild dysplasia-like changes were seen in 4 (18%) children; moderate changes were seen in 11 (50%) children and severe changes were seen in 7 (31.8%) children. No statistically significant relationships were detected between bone changes and the children’s age, age of starting deferoxamine, duration of therapy, or serum ferritin level.


A wider spectrum of deferoxamine-induced bone-dysplasia-like changes was recognized despite delayed onset and small doses of therapy. These changes should be considered as a possible cause of arthropathy in children with thalassemia major, especially symptomatic children.


Thalassemia Deferoxamine Dysplasia Bone 


  1. 1.
    Olivieri NF, Brittenham GM (1997) Iron-chelating therapy and the treatment of thalassemia. Blood 89:739–761PubMedGoogle Scholar
  2. 2.
    Chand G, Chowdhury V, Manchanda A et al (2009) Deferiprone-induced arthropathy in thalassemia: MRI findings in a case. Indian J Radiol Imaging 19:155–157PubMedCrossRefGoogle Scholar
  3. 3.
    De Virgiliis S, Congia M, Frau F et al (1988) Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr 113:661–669PubMedCrossRefGoogle Scholar
  4. 4.
    Hartkamp MJ, Babyn PS, Olivieri F (1993) Spinal deformities in deferoxamine-treated homozygous beta-thalassemia major patients. Pediatr Radiol 23:525–552PubMedCrossRefGoogle Scholar
  5. 5.
    Brill PW, Winchester P, Giardina PJ et al (1991) Deferoxamine-induced bone dysplasia in patients with thalassemia major. AJR Am J Roentgenol 156:561–565PubMedCrossRefGoogle Scholar
  6. 6.
    Orinoco C, Scutellari PN, Castaldi G (1992) Growth plate injury of the long bones in treated betathalassemia. Skeletal Radiol 21:39–44Google Scholar
  7. 7.
    De Sanctis V, Pinamonti A, Di Palma A et al (1996) Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine. Eur J Pediatr 155:368–372PubMedCrossRefGoogle Scholar
  8. 8.
    Olivieri NF, Koren G, Harris J et al (1992) Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol 14:48–56PubMedCrossRefGoogle Scholar
  9. 9.
    Arman MI, Bektas S (1989) Rheumatologic findings in patients with major and intermediate beta-thalassemia. Z Rheumatol 48:68–72PubMedGoogle Scholar
  10. 10.
    Naselli A, Vignolo M, Di Battista E et al (1998) Long-term follow-up of skeletal dysplasia in thalassemia major. J Pediatr Endocrinol Metab 3:817–825Google Scholar
  11. 11.
    Miller TT, Caldwell G, Kaye JJ et al (1993) MR imaging of deferoxamine-induced bone dysplasia in an 8-year-old female with thalassemia major. Pediatr Radiol 23:523–524PubMedCrossRefGoogle Scholar
  12. 12.
    Chan Y, Li C, Chu WC et al (2000) Deferoxamine-induced bone dysplasia in the distal femur and patella of pediatric patients and young adults: MR imaging appearance. AJR Am J Roentgenol 175:1561–1566PubMedCrossRefGoogle Scholar
  13. 13.
    Chan Y, Li C, Pang L et al (2002) Patterns of bone diseases in transfusion-dependent homozygous thalassemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Pediatr Radiol 32:492–497PubMedCrossRefGoogle Scholar
  14. 14.
    Munk PL, Helms CA, Holt RG (1989) Immature bone infarcts: findings on plain radiographs and MR scans. AJR Am J Roentgenol 152:547–549PubMedCrossRefGoogle Scholar
  15. 15.
    Jaramillo D, Shapiro F (1998) Growth cartilage: normal appearance, variants and abnormalities. Magn Reson Clin N Am 6:455–471Google Scholar
  16. 16.
    Chan Y, Li C, Pang L et al (2002) Desferrioxamine-induced long bone changes in thalassaemic patients—radiographic features, prevalence and relations with growth. Clin Radiol 55:610–614CrossRefGoogle Scholar
  17. 17.
    Lederman HM, Cohen A, Lee JW et al (1984) Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood 64:748–753PubMedGoogle Scholar
  18. 18.
    Estrov Z, Tawa A, Wang XH et al (1987) In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 69:757–761PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Hadeel M. Seif El Dien
    • 2
  • Reem I. Esmail
    • 1
  • Rania E. Magdy
    • 1
  • Hala M. Lotfy
    • 1
    • 3
    Email author
  1. 1.Department of Pediatrics, Faculty of MedicineCairo UniversityCairoEgypt
  2. 2.Department of Radiology, Faculty of MedicineCairo UniversityCairoEgypt
  3. 3.Department of Pediatric RheumatologyCairoEgypt

Personalised recommendations